Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada.
The company is developing products for the treatment and prevention of cancer based on its proprietary technologies. The company’s product development initiatives are focused primarily on technologies that modulate the tumour microenvironment.
The company’s proprietary technology platform, DOS47 has yielded two new drug product candidates, L-DOS47 and V-DOS47. L-DOS47 is under clinical stu...
Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada.
The company is developing products for the treatment and prevention of cancer based on its proprietary technologies. The company’s product development initiatives are focused primarily on technologies that modulate the tumour microenvironment.
The company’s proprietary technology platform, DOS47 has yielded two new drug product candidates, L-DOS47 and V-DOS47. L-DOS47 is under clinical study for the treatment of NSCLC. L-DOS47 has completed preclinical testing and manufacturing development, following which, regulatory approvals to conduct a Phase I/II clinical trial In Poland and a Phase I study in the U.S. were obtained. V-DOS47 has been licensed to the company’s wholly-owned Polish subsidiary for preclinical and clinical development. The V-DOS47 drug candidate uses the company’s proprietary DOS47 technology conjugated to anti-VEGFR2 antibody targeting a range of cancers.
The company has exclusive out-license agreement with Xisle Pharma Ventures Trust (Xisle) for the Company's late-stage, Biphasix technology platform, including the lead product candidate, interferon alpha. Xisle is responsible for the continued clinical development and subsequent commercialization of the product for the treatment of HPV-induced, low-grade, cervical intraepithelial lesions.
Intellectual Property
The company owns two U.S. patents in respect of the DOS47 technology, and also has also licensed patent rights from the NRC for the antibody component of L-DOS47. With respect to non-U.S. patents, the company owns 52 DOS47 related patents in other jurisdictions with various patent applications in countries worldwide.
The company has filed a joint patent application with NRC to protect the use of an antibody for use in cell-based therapies. In addition, the company has also filed new patent application covering the use of anti-VEGFR2 antibodies in cell-based therapy in July 2017.
The company has filed a Canadian Trade Mark Application for TUMOR DEFENSE BREAKER.
Agreements
The company has a collaboration agreement with Moffitt Cancer Center to perform basic research studies to further investigate the pharmacodynamics of L-DOS47 and determine the potential benefits of combining L-DOS47 with immune checkpoint inhibitors.
The company has a collaboration agreement with the Moffit Cancer Center to extract radiomics data using their proprietary HealthMyne platform from CT scans of late stage lung cancer patients treated with L-DOS47.